What does this research mean for the field?

In pediatric noninfectious posterior and panuveitis, ocular sequelae are nearly universal, with glaucoma and vitreous opacities driving visual decline, whereas methotrexate treatment is associated with visual preservation. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To describe clinical characteristics, ocular sequelae, and visual outcomes in pediatric patients treated for noninfectious posterior and panuveitis.

August 30, 2026Ocular Immunology and Inflammation

Clinical Features and Visual Outcomes of Pediatric Noninfectious Posterior and Panuveitis

View Full Paper

Ask AI

Bookmark

Authors

JMJustin C. MusteThomas Jefferson University JMJonathan MartinThomas Jefferson University TYTadashi YokoiWills Eye Hospital

Discussion

Member takes

Implication

Retrospective cohort study reveals visual preservation with methotrexate in pediatric posterior and panuveitis, indicating the protective role of early immunosuppression.

Key Points

To describe clinical characteristics, ocular sequelae, and visual outcomes in pediatric patients treated for noninfectious posterior and panuveitis.
Retrospective single-center cohort study evaluating children with noninfectious posterior or panuveitis between June 2015 and June 2025 (N = 69 patients, 106 eyes).
Patients with at least 3 months of follow-up (mean 42 months) were assessed using chart reviews and linear mixed-effects modeling of visual acuity trajectories.
Ocular complications were present in 98.1% of eyes, with severe visual impairment (20/200 or worse) remaining stable between baseline (39.1%) and final follow-up (40.6%).
Linear mixed-effects modeling showed that glaucoma (β×t = +0.0141 logMAR/month, p < 0.001) and vitreous opacities (β×t = +0.0096 logMAR/month, p = 0.005) were the primary drivers of visual decline.
Treatment with methotrexate was independently associated with a more favorable visual acuity trajectory over time (β×t = −0.0071 logMAR/month, p < 0.001).

Cite This Study

Muste et al. (2026) studied this question.

synapsesocial.com/papers/6a93f0b06c1a8fb52e79d014 https://doi.org/10.1080/09273948.2026.2723742

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study reveals visual preservation with methotrexate in pediatric posterior and panuveitis, indicating the protective role of early immunosuppression.

Clinical Features and Visual Outcomes of Pediatric Noninfectious Posterior and Panuveitis

Discussion

Member takes

Implication

Key Points

Cite This Study

Clinical Features and Visual Outcomes of Pediatric Noninfectious Posterior and Panuveitis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider